GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (FRA:5LB) » Definitions » Owner Earnings per Share (TTM)

BioVaxys Technology (FRA:5LB) Owner Earnings per Share (TTM) : -0.01 (As of Oct. 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioVaxys Technology Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

BioVaxys Technology's Owner Earnings per Share (TTM) ended in Oct. 2024 was €-0.01. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for BioVaxys Technology's Owner Earnings per Share (TTM) or its related term are showing as below:



FRA:5LB's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 30.005
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

BioVaxys Technology's Earnings per Share (Diluted) for the three months ended in Oct. 2024 was €-0.01. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2024 was €-0.01. It's PE Ratio (TTM) ratio for today is At Loss.

BioVaxys Technology's EPS without NRI for the three months ended in Oct. 2024 was €-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Oct. 2024 was €-0.01. It's PE Ratio without NRI ratio for today is At Loss.


BioVaxys Technology Owner Earnings per Share (TTM) Historical Data

The historical data trend for BioVaxys Technology's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Owner Earnings per Share (TTM) Chart

BioVaxys Technology Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - - -0.01

BioVaxys Technology Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -0.01

Competitive Comparison of BioVaxys Technology's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, BioVaxys Technology's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVaxys Technology's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where BioVaxys Technology's Price-to-Owner-Earnings falls into.


;
;

BioVaxys Technology Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

BioVaxys Technology's Owner Earnings per Share (TTM) Calculation:

Last Year Average of Last 5 Years
Net Income -2.64
Depreciation, Depletion and Amortization 0.00
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 0.71
Change In Working Capital 0.04
Shares Outstanding (Diluted Average) 195.72

1. Start with "Net Income" from income statement. BioVaxys Technology's Net Income for the trailing twelve months (TTM) ended in Oct. 2024 was €-2.64 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. BioVaxys Technology's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Oct. 2024 was €0.00 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. BioVaxys Technology's Change In Deferred Tax for the trailing twelve months (TTM) ended in Oct. 2024 was €0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = €0.71 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

BioVaxys Technology's 5-Year Average Maintenance Capital Expenditure = €0.71 Mil

5. "Change In Working Capital" is from cashflow statement. BioVaxys Technology's Change In Working Capital for the trailing twelve months (TTM) ended in Oct. 2024 was €0.04 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. BioVaxys Technology's Shares Outstanding (Diluted Average) for the months ended in Oct. 2024 was 195.719 Mil.

BioVaxys Technology's Onwer Earnings Per Share for Oct. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -2.639 +0+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-0.71+0.036)/195.719
=-0.01

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=0.025/-0.01
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


BioVaxys Technology Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVaxys Technology Business Description

Traded in Other Exchanges
Address
146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

BioVaxys Technology Headlines

No Headlines